HuGE Literature Finder
Records
1
-
4
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2016 Apr 27 (4): 693-9. Carter C A, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle L A, Steinberg S M, Xi L, Raffeld M, Tomita Y, Lee M J, Lee S, Trepel J B, Reckamp K L, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone |
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. British journal of cancer 2013 Nov 109 (11): 2803-9. Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa |
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Jun 24 (6): 1653-9. Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku |
Prognostic assessment of apoptotic gene polymorphisms in non-small cell lung cancer in Chinese. Journal of biomedical research 2013 May 27 (3): 231-8. Cao Songyu, Wang Cheng, Huang Xinen, Dai Juncheng, Hu Lingmin, Liu Yao, Chen Jiaping, Ma Hongxia, Jin Guangfu, Hu Zhibin, Xu Lin, Shen Hongbi |
- Page last reviewed:Jul 25, 2022
- Page last updated:Jan 27, 2023
- Content source: